The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.00
Bid: 102.00
Ask: 108.00
Change: 0.00 (0.00%)
Spread: 6.00 (5.882%)
Open: 105.00
High: 105.00
Low: 105.00
Prev. Close: 105.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Trading Update

7 Sep 2010 07:00

RNS Number : 2445S
Intercede Group PLC
07 September 2010
 



7 September 2010

Intercede Group plc

("Intercede")

 

Positive Trading Update

 

Intercede announces strong levels of business throughout the summer period.

The Healthcare sector has made a significant contribution to revenue and in July orders from an existing UK customer generated more than £800,000 in cash receipts. 

US government customers have continued to buy additional software licenses and a further US Federal Agency has purchased the Intercede MyID system. This brings the total number of Agencies using Intercede MyID for HSPD-12/PIV compliance to 13. Lockheed Martin and FAA continue to buy materially significant quantities of professional service time from Intercede in support of their large enterprise-wide identity programs.

Internationally, Intercede has added the Australian government and a South African bank to its customer list. Additional revenues are accruing for the next phase of the Kuwait national ID program and an existing customer that has purchased Intercede MyID to power a Switzerland-wide electronic identity service.

Intercede's sales activities continue to increase the pipeline of future business. A number of contract awards are also pending imminent closure, and the company is on target to meet full year expectations. Intercede remains in a strong cash position at the end of August.

Richard Parris, Chairman and Chief Executive of Intercede, said:

"Our level of business activity is at an all time high driven by repeat orders against existing contracts, new orders from new customers and a growing pipeline of high value prospects. Although, as expected, we have seen a reduction in UK Government orders compared to the same period last year, this is being compensated for by international orders, particularly from the US."

About Intercede

Intercede is the producer of the MyID Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organisations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalisation, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include more than 10 Federal Agencies, a program with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

For more information visit http://www.intercede.com

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7600 1658

Clive Carver

Sarah Wharry

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

Francesca Tuckett

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKKADDFBKDKCK
Date   Source Headline
10th Aug 20227:00 amRNSNotice of AGM
30th Jun 20227:00 amRNSBoard Changes
8th Jun 20227:00 amRNSFinal Results
25th May 202210:15 amRNSInvestor Presentation
12th Apr 20227:00 amRNSAppointment of CFO
6th Apr 20227:00 amRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSTrading Update & Contract Win
30th Mar 202210:01 amRNSReceipt of $3.4m Order
2nd Feb 20227:00 amRNSContract Win
8th Dec 20213:55 pmRNSDirector/PDMR Shareholding and Issue of Equity
23rd Nov 20217:00 amRNSHalf-year Report
19th Nov 20217:00 amRNSHolding(s) in Company-Amendment
17th Nov 20217:00 amRNSInvestor Presentation
16th Nov 20217:00 amRNSHolding(s) in Company
15th Nov 20213:45 pmRNSTotal Voting Rights
11th Nov 20214:12 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSTrading Update
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.